news
Tract Bio identifies drug targets for oesophageal cancer
Tract Bio’s new research reveals key insights into the evolution of oesophageal adenocarcinoma (EAC) and identifies promising drug combinations for more effective treatment.
List view / Grid view
Drug Targets
A drug target is anything within a living organism to which a drug is directed and/or binds, resulting in a change in its behaviour or function.
webinar
Solving the AOC puzzle: Strategies for chemistry, manufacturing and regulatory success
21 March 2025 | By Abzena
Watch our webinar with Abzena’s experts to explore practical solutions for overcoming chemistry, manufacturing and regulatory challenges in antibody-oligonucleotide conjugate (AOC) development, enabling progress for previously untreatable diseases.
webinar
Reprogramming immunity: designing smarter checkpoint receptor agonists
19 March 2025 | By Eurofins DiscoverX
Join Dr Daniela Cipolletta from Seismic Therapeutic to discover how FcγRIIb clustering enabled the discovery of S-4321, a low-affinity PD-1 agonist that restores immune balance by engaging multiple inhibitory pathways.
news
New AI algorithm searches 10 sextillion drug candidates
Scientists have developed an AI algorithm capable of searching through 10 sextillion potential drug molecules, a feat previously considered impossible. This method could significantly speed up drug discovery and the development of new treatments.
news
Rare diseases, big advances: how research is powering a new era of treatments
This Friday, February 28, marks Rare Disease Day 2025, a global initiative raising awareness for the 300 million people living with rare conditions. Dr David Reynolds, CEO of LoQus23 Therapeutics, explores how advancements in rare disease research are driving the development of new treatments.
news
Ginger-based compound targets inflammation in IBD
Researchers at the University of Toronto have discovered a compound in ginger, furanodienone (FDN), that interacts with the pregnane X receptor to reduce inflammation in the colon. This finding suggests FDN could be an effective, natural treatment for inflammatory bowel disease (IBD).
news
Study identifies new genetic targets for neuropsychiatric diseases
Scientists identify thousands of novel enhancers linked to neuronal differentiation and neuropsychiatric disorders, offering new pathways for drug discovery and potential therapeutic targets.
news
Study reveals 58 targets for heart failure drug development
A new study has identified novel drug targets for heart failure, focusing on two major types of the condition. These findings could lead to more effective, targeted treatments for both heart failure subtypes.
news
Azenta’s BioArc Ultra powers UK research
UK Biocentre has significantly expanded its sample storage capacity with the addition of Azenta's BioArc Ultra, adding space for 16 million more samples to support vital health research.
news
Restoring the gut: VE303’s strategy for C. diff relief
A new publication in Nature Medicine highlights the potential of VE303 for preventing recurrent C. difficile infection, detailing its impact on the gut microbiome and immune response.
article
New study explores safer antidepressants for pregnant women
A new study suggests that targeting serotonin in the gut, rather than the brain, could lead to antidepressants with fewer side effects.
news
UVA’s computer models target antibiotics to combat resistance
Researchers at the University of Virginia School of Medicine have developed computer models to create more targeted antibiotics. This approach aims to fight antibiotic resistance by focusing on specific bacteria in different parts of the body, reducing the reliance on broad-spectrum antibiotics.
webinar
The rise of organoids: a new era in drug discovery
17 January 2025 | By Drug Target Review
This webinar covers how organoids are reshaping drug discovery by providing more accurate models for disease research and drug testing, offering new solutions to long-standing challenges in the industry.
news
Collaboration aims to advance automated insulin technology for diabetes
UVA Center for Diabetes Technology and Tandem Diabetes Care partner to advance automated insulin delivery systems for diabetes management.
news
LB Pharmaceuticals announces positive schizophrenia trial data
LB Pharmaceuticals announced positive Phase II results for LB-102, showing significant symptom improvement in schizophrenia with a favourable safety profile.
